Effects of treatment with a 5-HT 4 receptor antagonist in heart failure

British Journal of Pharmacology

Volumn 150, Issue 2, 2007, Pages 143-152

  Birkeland, J A K ^a   Sjaastad, I ^a,b   Brattelid, T ^a   Qvigstad, E ^a   Moberg, E R ^a   Krobert, K A ^a   Bjornerheim R ^a,b   Skomedal, T ^a   Sejersted, O M ^a   Osnes, J B ^a   Levy, F O ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

5 HT; 5 HT 4 receptor blockade; Congestive heart failure; Piboserod; SB207266

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ATROPINE; BETA ADRENERGIC RECEPTOR; ISOPRENALINE; MESSENGER RNA; PIBOSEROD; PLACEBO; PRAZOSIN; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 4 ANTAGONIST; SEROTONIN 4 RECEPTOR; SEROTONIN 4B RECEPTOR; TIMOLOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EX VIVO STUDY; HEART FUNCTION; HEART OUTPUT; HEART PAPILLARY MUSCLE; HEART VENTRICLE CONTRACTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; IN VIVO STUDY; INOTROPISM; MALE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; UPREGULATION;

ADRENERGIC BETA-AGONISTS; ANIMALS; CARDIAC OUTPUT; HEART FAILURE, CONGESTIVE; INDOLES; ISOPROTERENOL; LUNG; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; ORGAN SIZE; PIPERIDINES; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, SEROTONIN, 5-HT4; RNA, MESSENGER; UP-REGULATION; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 33846496073     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706966     Document Type: Article

References (53)

1. 4(i). Naunyn-Schmiedeberg's Arch Pharmacol 369: 616-628.
2. 4 mRNA in heart failure. Naunyn-Schmiedeberg's Arch Pharmacol 370: 157-166.
3. Bristow MR (2000). β-Adrenergic receptor blockade in chronic heart failure. Circulation 101: 558-569.
4. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K et al. (1982). Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 307: 205-211.
5. Doughty RN, Whalley GA, Walsh HA, Gamble GD, Lopez-Sendon J, Sharpe N (2004). Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the Capricorn Echo Substudy. Circulation 109: 201-206.
6. Engelhardt S, Böhm M, Erdmann E, Lohse MJ (1996). Analysis of beta1-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of beta1-adrenergic receptor mRNA in heart failure. J Am Coll Cardiol 27: 146-154.
7. Finsen AV, Christensen G, Sjaastad I (2005). Echocardiographic parameters discriminating myocardial infarction with pulmonary congestion from myocardial infarction without congestion in the mouse. J Appl Physiol 98: 680-689.
8. Frantz RP, Olson LJ, Grill D, Moualla SK, Nelson SM, Nobrega TP et al. (2005). Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am Heart J 149: 541-547.
9. 4 receptor antagonist amide with oral activity. J Med Chem 38: 4760-4763.
10. 2-adrenoceptors in human atrial myocardium. Circ Res 66: 1610-1623.
11. Hasenfuss G, Holubarsch C, Blanchard EM, Mulieri LA, Alpert NR, Just H (1989). Influence of isoprenaline on myocardial energetics. Experimental and clinical investigations. Basic Res Cardiol 84 (Suppl 1): 147-155.
12. Hoshijima M, Sah VP, Wang Y, Chien KR, Brown JH (1998). The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho kinase. J Biol Chem 273: 7725-7730.
13. Houser SR, Piacentino III V, Weisser J (2000). Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol 32: 1595-1607.
14. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ et al. (1994). International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 46: 157-203.
15. Ishikawa Y, Sorota S, Kiuchi K, Shannon RP, Komamura K, Katsushika S et al. (1994). Downregulation of adenylylcyclase types V and VI mRNA levels in pacing-induced heart failure in dogs. J Clin Invest 93: 2224-2229.
16. Jahnel U, Nawrath H, Rupp J, Ochi R (1993). L-type calcium channel activity in human atrial myocytes as influenced by 5-HT. Naunyn- Schmiedeberg's Arch Pharmacol 348: 396-402.
17. Karram T, Abbasi A, Keidar S, Golomb E, Hochberg I, Winaver J et al. (2005). Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. Am J Physiol Heart Circ Physiol 289: H1351-H1358.
18. 2-adrenoceptors mediate catecholamine-evoked arrhythmias in isolated human right atrium. Naunyn-Schmiedeberg's Arch Pharmacol 348: 536-540.
19. 4 receptors in human atrium: facilitation by chronic β-adrenoceptor blockade. Naunyn-Schmiedeberg's Arch Pharmacol 349: 331-337.
20. Kaumann AJ, Sanders L, Brown AM, Murray KJ, Brown MJ (1990). A 5-hydroxytryptamine receptor in human atrium. Br J Pharmacol 100: 879-885.
21. Läer S, Remmers F, Scholz H, Stein B, Müller FU, Neumann J (1998). Receptor mechanisms involved in the 5-HT-induced inotropic action in the rat isolated atrium. Br J Pharmacol 123: 1182-1188.
22. Laser A, Neubauer S, Tian R, Hu K, Gaudron P, Ingwall JS et al. (1996). Long-term beta-blocker treatment prevents chronic creatine kinase and lactate dehydrogenase system changes in rat hearts after myocardial infarction. J Am Coll Cardiol 27: 487-493.
23. Lohse MJ, Engelhardt S, Eschenhagen T (2003). What is the role of β-adrenergic signaling in heart failure? Circ Res 93: 896-906.
24. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D et al. (2002). Myocardial gene expression in dilated cardiomyopathy treated with β-blocking agents. N Engl J Med 346: 1357-1365.
25. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N et al. (2000). PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101: 365-376.
26. Nicolosi GL, Latini R, Marino P, Maggioni AP, Barlera S, Franzosi MG et al. (1996). The prognostic value of predischarge quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Eur Heart J 17: 1646-1656.
27. 1-blockade improves cardiac bioenergetics and function and decreases neuroendocrine activation in rats during early postinfarct remodeling. Biochem Biophys Res Commun 281: 491-498.
28. 1-blockade attenuates post-infarct remodelling without improvement in myocardial energy metabolism and function in rats with heart failure. Eur J Heart Fail 5: 725-732.
29. Otorii T, Takeda K, Katano Y, Nakagawa Y, Imai S (1977). Effects of catecholamines on the myocardial redox potential. Jpn J Pharmacol 27: 553-562.
30. 4 receptors. Mol Pharmacol 41: 346-351.
31. Pau D, Workman AJ, Kane KA, Rankin AC (2003). Electrophysiological effects of 5-hydroxytryptamine on isolated human atrial myocytes, and the influence of chronic β-adrenoceptor blockade. Br J Pharmacol 140: 1434-1441.
32. Plank DM, Yatani A, Ritsu H, Witt S, Glascock B, Lalli MJ et al. (2003). Calcium dynamics in the failing heart: restoration by β-adrenergic receptor blockade. Am J Physiol Heart Circ Physiol 285: H305-H315.
33. 13 protein. J Biol Chem 277: 20812-20819.
34. Poole-Wilson PA (2003). ACE inhibitors and ARBs in chronic heart failure: the established, the expected, and the pragmatic. Med Clin North Am 87: 373-389.
35. 4 receptor-mediated inotropic response to serotonin in heart failure. Cardiovasc Res 65: 869-878.
36. 4 receptors induced in the acute failing heart. Circ Res 97: 268-276.
37. Rajagopalan S, Pitt B (2003). Aldosterone as a target in congestive heart failure. Med Clin North Am 87: 441-457.
38. Sanbe A, Takeo S (1995). Long-term treatment with angiotensin I-converting enzyme inhibitors attenuates the loss of cardiac β-adrenoceptor responses in rats with chronic heart failure. Circulation 92: 2666-2675.
39. 4 receptors by chronic β-blocker treatment. Circulation 92: 2526-2539.
40. 2 receptor systems in human atrium: role of cyclic nucleotides. Naunyn-Schmiedeberg's Arch Pharmacol 353: 661-670.
41. Sharpe N, Murphy J, Smith H, Hannan S (1988). Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1: 255-259.
42. iα-proteins in patients with congestive heart failure. Eur J Clin Pharmacol 51: 127-132.
43. 1- vs β-adrenoceptor-mediated inotropic response in rats with congestive heart failure. Acta Physiol Scand 177: 449-458.
44. Sjaastad I, Sejersted OM, Ilebekk A, Bjørnerheim R (2000). Echocardiographic criteria for detection of post-infarction congestive heart failure in rats. J Appl Physiol 89: 1445-1454.
45. 1-adrenoceptor-mediated and β-adrenoceptor- mediated inotropic components elicited by norepinephrine in failing human ventricular muscle. J Pharmacol Exp Ther 280: 721-729.
46. 1-adrenergic receptor transgenic mice. J Mol Cell Cardiol 35: 389-397.
47. Sun YL, Hu SJ, Wang LH, Hu Y, Zhou JY (2005). Effect of β-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. Chest 128: 1812-1821.
48. Ungerer M, Parruti G, Böhm M, Puzicha M, DeBlasi A, Erdmann E et al. (1994). Expression of β-arrestins and β-adrenergic receptor kinases in the failing human heart. Circ Res 74: 206-213.
49. Vaughan DE, Pfeffer MA (1994). Post-myocardial infarction ventricular remodeling: animal and human studies. Cardiovasc Drugs Ther 8: 453-460.
50. Wang J, Guo X, Dhalla NS (2004). Modification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril or losartan. Biochim Biophys Acta 1690: 177-184.
51. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ (1987). Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76: 44-51.
52. Yasumura Y, Takemura K, Sakamoto A, Kitakaze M, Miyatake K (2003). Changes in myocardial gene expression associated with beta-blocker therapy in patients with chronic heart failure. J Card Fail 9: 469-474.
53. Yue P, Long CS, Austin R, Chang KC, Simpson PC, Massie BM (1998). Post-infarction heart failure in the rat is associated with distinct alterations in cardiac myocyte molecular phenotype. J Mol Cell Cardiol 30: 1615-1630.